» Articles » PMID: 15247320

Pentobarbital Differentially Modulates Alpha1beta3delta and Alpha1beta3gamma2L GABAA Receptor Currents

Overview
Journal Mol Pharmacol
Date 2004 Jul 13
PMID 15247320
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

GABAA receptors are modulated by a variety of compounds, including the neurosteroids and barbiturates. Although the effects of barbiturates on alphabetagamma isoforms, thought to dominate phasic (synaptic) GABAergic inhibition, have been extensively studied, the effects of pentobarbital on kinetic properties of alphabetadelta GABAA receptors, thought to mediate tonic (extra- or perisynaptic) inhibition, are unknown. Using ultrafast drug delivery and single channel recording techniques, we demonstrate isoform-specific pentobarbital modulation of low-efficacy, minimally desensitizing alpha1beta3 currents and high-efficacy, rapidly desensitizing alpha1beta3gamma2L currents. Specifically, with saturating concentrations of GABA, pentobarbital substantially potentiated peak alpha1beta3delta receptor currents but failed to potentiate peak alpha1beta3gamma2L receptor currents. Also, pentobarbital had opposite effects on the desensitization of alpha1beta3delta (increased) and alpha1beta3gamma2L (decreased) receptor currents evoked by saturating GABA. Pentobarbital increased steady-state alpha1beta3delta receptor single channel open duration primarily by introducing a longer duration open state, whereas for alpha1beta3gamma2L receptor channels, pentobarbital increased mean open duration by increasing the proportion and duration of the longest open state. The data support previous suggestions that GABA may be a partial agonist at alphabetadelta isoforms, which may render them particularly sensitive to allosteric modulation. The remarkable increase in gating efficacy of alpha1beta3delta receptors suggests that alphabetadelta isoforms, and by inference tonic forms of inhibition, may be important targets for barbiturates.

Citing Articles

Potentiation of the GABAR reveals variable energetic contributions by etiocholanolone and propofol.

Pierce S, Xu S, Germann A, Steinbach J, Akk G Biophys J. 2023; 123(14):1954-1967.

PMID: 37752702 PMC: 11442032. DOI: 10.1016/j.bpj.2023.09.014.


Non-sedative cortical EEG signatures of allopregnanolone and functional comparators.

Lambert P, Ni R, Benz A, Rensing N, Wong M, Zorumski C Neuropsychopharmacology. 2022; 48(2):371-379.

PMID: 36168047 PMC: 9751067. DOI: 10.1038/s41386-022-01450-x.


GABA receptors in GtoPdb v.2021.3.

Belelli D, Hales T, Lambert J, Luscher B, Olsen R, Peters J IUPHAR BPS Guide Pharm CITE. 2022; 2021(3).

PMID: 35005623 PMC: 8734037. DOI: 10.2218/gtopdb/F72/2021.3.


Reduced Activation of the Synaptic-Type GABA Receptor Following Prolonged Exposure to Low Concentrations of Agonists: Relationship between Tonic Activity and Desensitization.

Pierce S, Germann A, Evers A, Steinbach J, Akk G Mol Pharmacol. 2020; 98(6):762-769.

PMID: 32978327 PMC: 7673486. DOI: 10.1124/molpharm.120.000088.


Molecular and Regulatory Mechanisms of Desensitization and Resensitization of GABA Receptors with a Special Reference to Propofol/Barbiturate.

Kang Y, Saito M, Toyoda H Int J Mol Sci. 2020; 21(2).

PMID: 31952324 PMC: 7014398. DOI: 10.3390/ijms21020563.